Latest Tekmira Pharmaceuticals Corp (TKMR) Headlines
Nasdaq stocks posting largest percentage decreases
AP - 51 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Tekmira Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Thu Mar 13, 8:02AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has priced an underwritten public offering of 2,125,000 shares of its common stock at a price of US$28.50 per share for aggregate gross proceeds of US$60,562,500, before deducting underwriting discounts and commissions and other estimated offering expenses. Tekmira has also granted the underwriters a 30-day option to purchase up to an additional 318,750 shares to cover over-allotments, if any, which would result in additional gross proceeds. The offering is expected to close on or about March 18, 2014, subject to the satisfaction of customary closing conditions.
Tekmira Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 10, 3:40PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it is offering to sell shares of its common stock in an underwritten public offering to raise gross proceeds of approximately US$60 million. Tekmira also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Tekmira, with net proceeds to be used to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Tekmira Provides Corporate Update and Announces Year-End 2013 Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today its 2013 audited financial results and provided a corporate update.
TEKMIRA PHARMACEUTICALS
at Investor's Business Daily - Wed Mar 05, 5:35PM CST
TEKMIRA PHARMACEUTICALS (TKMR) got FDA fast-track designation for its anti-Ebola viral therapy. Shares jumped 8.5% after soaring 39.7% in the regular session.
Tekmira Receives Fast Track Designation From FDA for Its Anti-Ebola Viral Therapeutic
GlobeNewswire - Wed Mar 05, 3:06PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic.
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2013 Year-End Financial Results
GlobeNewswire - Tue Mar 04, 3:07PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Thursday, March 6, 2014 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to provide a corporate update and report 2013 year-end financial results.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Which Themes in Biotech Today are Bankable?
Chris Ahlstrand, The Motley Fool - Motley Fool - Tue Feb 25, 5:30PM CST
Sometimes the best way to get started in biotech investing is to analyze specific technologies within the industry. The science and our knowledge of how diseases work is constantly evolving, and every now and then breakthroughs take place which...
Tekmira Presents Recent Advances in mRNA Delivery at Scientific Symposium
GlobeNewswire - Tue Feb 25, 3:47AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA therapeutics, announced that recent advances in the enablement of messenger RNA (mRNA) using Tekmira's lipid nanoparticle (LNP) technology were presented by Tekmira's Chief Technical Officer, Dr. Ian MacLachlan, at the AsiaTIDES Conference taking place in Tokyo, Japan from February 25-27, 2014.
DoD's Joint Project Manager Medical Countermeasure Systems (JPM-MCS) Announces Start of Human Clinical Trial for Ebola Therapeutic
PR Newswire - Mon Feb 24, 6:00AM CST
JPM Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office announced the dosing of the first subject in a Phase 1 clinical trial of TKM-Ebola. The anti-Ebola viral therapeutic is being developed by MCS-BDTX through a contract with Tekmira Pharmaceuticals Corporation.
Tekmira Announces Filing of Shelf Prospectus and Registration Statement
GlobeNewswire - Fri Feb 21, 1:54PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a developer of RNA interference (RNAi) therapeutics, today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10.
Webcast Advisory: Tekmira to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
GlobeNewswire - Thu Feb 20, 4:09PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark Murray, President and CEO of Tekmira, will provide a corporate overview at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 3:05 pm ET at the New York Palace Hotel.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013 Report
M2 - Tue Feb 18, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/ssk4w8/adrenocortical) has announced the addition of the "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013" report to their offering. 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Scope - A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer). - A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview Therapeutics Development Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis Drug Profiles axitinib - Drug Profile AT-101 - Drug Profile cintredekin besudotox - Drug Profile TKM-PLK1 - Drug Profile ATR-101 - Drug Profile Steroidogenic Factor-1 Antagonists - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Tekmira Pharmaceuticals Corp. Pfizer Inc. Insys Therapeutics, Inc. Ascenta Therapeutics, Inc. Orphagen Pharmaceuticals, Inc. Atterocor, Inc. For more information visit http://www.researchandmarkets.com/research/ss...nocortical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nasdaq stocks posting largest percentage decreases
AP - 51 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Tekmira Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Thu Mar 13, 8:02AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has priced an underwritten public offering of 2,125,000 shares of its common stock at a price of US$28.50 per share for aggregate gross proceeds of US$60,562,500, before deducting underwriting discounts and commissions and other estimated offering expenses. Tekmira has also granted the underwriters a 30-day option to purchase up to an additional 318,750 shares to cover over-allotments, if any, which would result in additional gross proceeds. The offering is expected to close on or about March 18, 2014, subject to the satisfaction of customary closing conditions.
Tekmira Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 10, 3:40PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it is offering to sell shares of its common stock in an underwritten public offering to raise gross proceeds of approximately US$60 million. Tekmira also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Tekmira, with net proceeds to be used to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Tekmira Provides Corporate Update and Announces Year-End 2013 Results
GlobeNewswire - Thu Mar 06, 6:30AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today its 2013 audited financial results and provided a corporate update.
TEKMIRA PHARMACEUTICALS
at Investor's Business Daily - Wed Mar 05, 5:35PM CST
TEKMIRA PHARMACEUTICALS (TKMR) got FDA fast-track designation for its anti-Ebola viral therapy. Shares jumped 8.5% after soaring 39.7% in the regular session.
Tekmira Receives Fast Track Designation From FDA for Its Anti-Ebola Viral Therapeutic
GlobeNewswire - Wed Mar 05, 3:06PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic.
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2013 Year-End Financial Results
GlobeNewswire - Tue Mar 04, 3:07PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Thursday, March 6, 2014 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to provide a corporate update and report 2013 year-end financial results.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Which Themes in Biotech Today are Bankable?
Chris Ahlstrand, The Motley Fool - Motley Fool - Tue Feb 25, 5:30PM CST
Sometimes the best way to get started in biotech investing is to analyze specific technologies within the industry. The science and our knowledge of how diseases work is constantly evolving, and every now and then breakthroughs take place which...
Tekmira Presents Recent Advances in mRNA Delivery at Scientific Symposium
GlobeNewswire - Tue Feb 25, 3:47AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA therapeutics, announced that recent advances in the enablement of messenger RNA (mRNA) using Tekmira's lipid nanoparticle (LNP) technology were presented by Tekmira's Chief Technical Officer, Dr. Ian MacLachlan, at the AsiaTIDES Conference taking place in Tokyo, Japan from February 25-27, 2014.
DoD's Joint Project Manager Medical Countermeasure Systems (JPM-MCS) Announces Start of Human Clinical Trial for Ebola Therapeutic
PR Newswire - Mon Feb 24, 6:00AM CST
JPM Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office announced the dosing of the first subject in a Phase 1 clinical trial of TKM-Ebola. The anti-Ebola viral therapeutic is being developed by MCS-BDTX through a contract with Tekmira Pharmaceuticals Corporation.
Tekmira Announces Filing of Shelf Prospectus and Registration Statement
GlobeNewswire - Fri Feb 21, 1:54PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a developer of RNA interference (RNAi) therapeutics, today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10.
Webcast Advisory: Tekmira to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
GlobeNewswire - Thu Feb 20, 4:09PM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark Murray, President and CEO of Tekmira, will provide a corporate overview at the 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25, 2014 at 3:05 pm ET at the New York Palace Hotel.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013 Report
M2 - Tue Feb 18, 2:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/ssk4w8/adrenocortical) has announced the addition of the "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013" report to their offering. 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Scope - A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma (Adrenal Cortex Cancer). - A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview Therapeutics Development Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis Drug Profiles axitinib - Drug Profile AT-101 - Drug Profile cintredekin besudotox - Drug Profile TKM-PLK1 - Drug Profile ATR-101 - Drug Profile Steroidogenic Factor-1 Antagonists - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Tekmira Pharmaceuticals Corp. Pfizer Inc. Insys Therapeutics, Inc. Ascenta Therapeutics, Inc. Orphagen Pharmaceuticals, Inc. Atterocor, Inc. For more information visit http://www.researchandmarkets.com/research/ss...nocortical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
